# Pierre Drion

> Pierre Drion is a Series A investor at Petercam (Brussels) backing Biotechnology and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Petercam](https://shizune.co/investors/profile/petercam)
- Location: Brussels, Belgium
- Total investments: 5
- Last investment: Jun 2023
- Lead investor: 20%
- Last updated: Aug 2026

Pierre Drion is a Series A investor at Petercam in Brussels focused on Biotechnology and Health Care. Pierre Drion - CEO @ Petercam

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $8.6M–$14M |
| Series B | $18M–$23M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 100% |
| Health Care | 3 | 60% |
| Life Science | 2 | 40% |
| Therapeutics | 2 | 40% |
| Medical | 1 | 20% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Series B | 2 | 40% |
| Funding Round | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Santero Therapeutics | Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms. | $8.6M | Series A | Jun 07, 2023 |  |
| Novadip Biosciences | Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction. | $23.4M | Series B | Nov 03, 2022 |  |
| A-Mansia Biotech | A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host. | $14.3M | Series A | Apr 27, 2018 |  |
| Ovizio | Ovizio develops digital holographic interferometric microscopy products. It builds 4D microscopic imaging devices and software based on digital holographic microscopy. Ovizio offers oLine 4D, a research and development, and diagnostic desktop device that is used without specific sample preparation, as well as with automatic compensation ofscratches or distortions on the sample support; iLine 4D, a multipurpose device for applications, such as inline or online flow monitoring or direct monitoring of cell cultures in bioreactors; and OsOne software for visualization, analysis, and archiving of images captured by the imaging devices. It also provides ILine F, a device that captures suspension cell culture process in real time; iLine M, an instrument that monitors cell confluence in multi layer vessels; iLine S, an equipment that monitors reproducibility of fragile cell; and QMod, a holographic and fluorescene microscopy. Scientists in the areas of pharmaceutical and biotech research and development use the products of Ovizio. Philip Mathuis and Serge Jooris founded it in 2009, with its headquarters in Brussels in Belgium. | $8.8M |  | Nov 16, 2015 |  |
| Ogeda | Ogeda (formerly named Euroscreen) is a Belgium-based, privately owned clinical-stage drug discovery company that invents and develops small molecule drug candidates targeting GPCRs. Ogeda's orally-available and proprietary lead drug candidate fezolinetant (ESN364) is currently in Phase2 clinical development for the treatment of women'shealth disorders. Ogeda has additional small molecules targeting GPCRs in pre-clinical development in multiple therapeutic areas including inflammatory and autoimmune diseases. Ogeda is backed by leading investors, including Vealius Biocapital II SA Sicar, Fund+ NV, SRIW SA, Capricorn Health-Tech Fund NVHT fund, BNP Paribas Fortis Private Equity Management SA. For more information, please visit: www.ogeda.com | $17.6M | Series B | Oct 02, 2015 |  |

5 of 5 investments shown.

## Co-investors
- [New Science Ventures](https://shizune.co/investors/profile/new-science-ventures) — VC Fund, 2 deals together
- [S.R.I.W.](https://shizune.co/investors/profile/s-r-i-w) — VC Fund, 2 deals together
- [the SRIW Life Sciences](https://shizune.co/investors/profile/the-sriw-life-sciences) — VC Fund, 2 deals together
- [BNP Paribas Fortis](https://shizune.co/investors/profile/bnp-paribas-fortis) — VC Fund, 1 deal together
- [Capricorn Partners](https://shizune.co/investors/profile/capricorn-partners) — VC Fund, 1 deal together
- [CR-CP Life Science Fund](https://shizune.co/investors/profile/cr-cp-life-science-fund) — VC Fund, 1 deal together

## About Petercam

VC Fund



1 contacts available at Petercam.

| Name | Title | Profile |
| --- | --- | --- |
| Pierre Drion | CEO | https://shizune.co/investors/profile/pierre-drion |

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Biotechnology Angel Investors in Europe](https://shizune.co/investors/biotechnology-angel-investors-europe)
- [Health Care Investors in Belgium](https://shizune.co/investors/health-care-investors-belgium)
- [Biotech Angel Investors in Europe](https://shizune.co/investors/biotech-angel-investors-europe)
- [All Angel Investors in Belgium](https://shizune.co/investors/angel-investors-belgium)
- [Life Science Angel Investors](https://shizune.co/investors/life-science-angel-investors)
- [Biotechnology Angel Investors in Belgium](https://shizune.co/investors/biotechnology-angel-investors-belgium)

## FAQ

### What does Pierre Drion invest in?

Pierre Drion invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Pierre Drion's check size?

Pierre Drion typically joins rounds of $8.6M–$14M at Series A and $18M–$23M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Pierre Drion participates in.

### When did Pierre Drion last invest?

The most recent investment recorded for Pierre Drion closed in Jun 2023. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co